Relapsed or Refractory Diffuse Large B Cell Lymphoma Market, By Drug Type (Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta, Others), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin Americ
Relapsed or Refractory Diffuse Large B Cell Lymphoma Market, By Drug Type (Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta, Others), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Middle East & Africa, and Asia Pacific)
Diffuse large B cell lymphoma (DLBCL) is the most common lymphoma that account forabout 25% to 30% of all non-Hodgkin lymphoma. This disease presents as a rapidly growing mass or enlarging lymph nodes in a nodal or extranodal site. Though aggressive, it does respond well to chemotherapy. It can affect many organ systems, and is best managed by an interprofessional team including the medical oncologist, radiation oncologist, and nephrologists. Radiation therapy can be needed in extranodal lymphomas. Kidney involvement has been well documented in patients with lymphoma. It is important to get the nephrologist involved early in the course of the disorder as renal failure is a complication of DLBCL itself, or renal failure can manifest during treatment. Careful assessment of the renal indices including acid-base, electrolytes, and volume status, should be assessed. The introduction of new drug with different technological platform and Mechanism of Action can contribute to market expansion. Thus, introduction of such advanced products in the market is expected to drive growth of the global relapsed or refractory diffuse large B cell lymphoma market over the forecast period.
Market Dynamics
The key players in the pharmaceutical industry are focusing on development of platform based drug for relapsed or refractory diffuse large B cell lymphoma. Thus, introduction of such advanced products in the market is expected to drive growth of the global relapsed or refractory diffuse large B cell lymphoma market over the forecast period. For instance, on September 29, 2023, Regeneron Pharmaceuticals, Inc., a leading biotechnology company, announced that the U.S. Food and Drug Administration (FDA) had accepted for Priority Review the Biologics License Application (BLA) for odronextamab to treat adult patients with relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL), who have progressed after at least two prior systemic therapies. The target action date for the FDA decision is March 31, 2024. Odronextamab is an investigational CD20xCD3 bispecific antibody designed to bridge CD20 on cancer cells with CD3-expressing T cells to facilitate local T-cell activation and cancer-cell killing.
Key features of the study:
This report provides an in-depth analysis of the global relapsed or refractory diffuse large B cell lymphoma market and provides market size (US$ Mn ) and compound annual growth rate (CAGR) for the forecast period (2023–2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global relapsed or refractory diffuse large B cell lymphoma market based on the following parameters– company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include MorphoSys U.S. Inc., Bristol Myers Squibb, Karyopharm Therapeutics, F.Hoffmann-La Roche AG, Merck & Co., Inc., Gilead Sciences, Inc., Novartis AG, Regeneron Pharmaceuticals, Cellular Biomedicine Group Inc., Genmab A/S, Incyte, AbbVie Inc., Janssen Biotech, Inc., Pfizer Inc., IMV Inc., Overland Pharmaceuticals (CY) Inc., ADC Therapeutics SA, Eagle Pharmaceuticals, Inc., and Adaptive Biotechnologies Corporation
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global relapsed or refractory diffuse large B cell lymphoma market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global relapsed or refractory diffuse large B cell lymphoma market
Detailed Segmentation:
By Drug Type:
Monjuvi
XPOVIO
Polivy
Kymriah
Yescarta
Others
By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
By Region:
North America
Latin America
Europe
Asia Pacific
Middle East
Africa
Company Profiles
MorphoSys U.S. Inc.
Bristol-Myers Squibb Company
Karyopharm Therapeutics
F. Hoffmann-La Roche AG
Merck & Co., Inc.
Gilead Sciences, Inc.
Novartis AG
Regeneron Pharmaceuticals
Cellular Biomedicine Group Inc.
Genmab A/S
Incyte
AbbVie Inc.
Janssen Biotech, Inc.
Pfizer Inc.
IMV Inc.
Overland Pharmaceuticals (CY) Inc.
ADC Therapeutics SA
Eagle Pharmaceuticals, Inc.
Adaptive Biotechnologies Corporation
1. Research Objective and Assumption
Research Objectives
Assumptions
Abbreviations
2. Market Purview
Report Description
Market Definition and Scope
Executive Summary
Market Snippet, By Drug Type
Market Snippet, By Distribution Channel
Market Snippet, By Region
Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Drivers
Restraints
Market Opportunities
Impact Analysis
Recent Trends
Recent Product Launches/Approvals
Mergers, Acquisitions, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis
PORTER’s Analysis
4. Global Relapsed or Refractory Diffuse Large B Cell Lymphoma Market – COVID-19 Impact Analysis
Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand
5. Global Relapsed or Refractory Diffuse Large B Cell Lymphoma Market, By Drug Type, 2018–2030, (US$ Mn)
Introduction
Market Share Analysis, 2023 and 2030 (%)
Y-o-Y Growth Analysis, 2019–2030
Segment Trends
Monjuvi
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Mn)
XPOVIO
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Mn)
Segment Trends
Polivy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Mn)
Segment Trends
Kymriah
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Mn)
Segment Trends
Yescarta
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Mn)
Segment Trends
Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Mn)
Segment Trends
6. Global Relapsed or Refractory Diffuse Large B Cell Lymphoma Market, By Distribution Channel, 2018–2030, (US$ Mn)
Introduction
Market Share Analysis, 2023 and 2030 (%)
Y-o-Y Growth Analysis, 2019–2030
Segment Trends
Hospitals Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Mn)
Retail Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Mn)
Online Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Mn)
7. Global Relapsed or Refractory Diffuse Large B Cell Lymphoma Market, By Region, 2018–2030, (US$ Mn)
Introduction
Market Share Analysis, 2023 and 2030 (%)
Y-o-Y Growth Analysis, 2019–2030
Segment Trends
North America
Introduction
Market Size and Forecast, and Y-o-Y Growth, a By Drug Type, 2018–2030, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018–2030, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2018–2030, (US$ Mn)
U.S.
Canada
Europe
Introduction
Market Size and Forecast, and Y-o-Y Growth, a By Drug Type, 2018–2030, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018–2030, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2018–2030, (US$ Mn)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
Introduction
Market Size and Forecast, and Y-o-Y Growth, a By Drug Type, 2018–2030, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018–2030, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2018–2030, (US$ Mn)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
Introduction
Market Size and Forecast, and Y-o-Y Growth, a By Drug Type, 2018–2030, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018–2030, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2018–2030, (US$ Mn)
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
Introduction
Market Size and Forecast, and Y-o-Y Growth, a By Drug Type, 2018–2030, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018–2030, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2018–2030, (US$ Mn)
GCC
Israel
Rest of Middle East
Africa
Introduction
Market Size and Forecast, and Y-o-Y Growth, a By Drug Type, 2018–2030, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018–2030, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2018–2030, (US$ Mn)
North Africa
Central Africa
South Africa
8. Competitive Landscape
Company Profiles
MorphoSys US Inc.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
Bristol-Myers Squibb Company
Karyopharm Therapeutics
F. Hoffmann-La Roche AG
Merck & Co., Inc.
Gilead Sciences, Inc.
Novartis AG
Regeneron Pharmaceuticals, Inc.
Cellular Biomedicine Group Inc.
Genmab A/S
Incyte
AbbVie Inc.
Janssen Biotech, Inc.
Pfizer Inc.
IMV Inc.
Overland Pharmaceuticals (CY) Inc.
ADC Therapeutics SA
Eagle Pharmaceuticals, Inc.
Adaptive Biotechnologies Corporation
Analysts’ Views
9. Section
References
Research Methodology
About us and Sales Contact
*Browse 26 market data tables and 26 figures on “Global Relapsed or Refractory Diffuse Large B Cell Lymphoma Market” – Global forecast to 2030